**Supplementary Table S1\_Schedules of carboplatin and etoposide chemotherapy**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Schedules** | **Any line****n = 123** | **Fist-line****n = 106** | **Second-line****n = 16** | **Third-line****n = 1** |
|  |  |  |  |  |
| CarboEtop-1 | 54 (43.9%) | 47 (44.3%) | 7 (43.7%) | 0 |
| CarboEtop-2 | 28 (22.8%) | 22 (20.7%) | 5 (31.2%) | 1 (100%) |
| CarboEtop-3 | 40 (32.5%) | 37 (34.9%) | 3 (18.7%) | 0 |
| CarboEtop-4 | 1 (0.8%) | 0 | 1 (6.2%) | 0 |
|  |  |  |  |  |
| CarboEtop (oral etoposide) | 55 (44.7%) | 48 (45.3%) | 7 (43.7%) | 0 |
| CarboEtop (i.v. etoposide) | 68 (55.3%) | 58 (54.7%) | 9 (56.2%) | 1 (100%) |

n = number of courses of chemotherapy; CarboEtop = carboplatin and etoposide chemotherapy; CarboEtop-1; etoposide 50 mg twice daily orally from day 1 to day 7 (included) followed by carboplatin area under the curve (AUC) 5 intravenously on day 8, every 28 days; CarboEtop-2; etoposide 120 mg/m2 intravenously on days 1, 2, and 3, and carboplatin AUC 5 or 6 intravenously on day 1, every 21 days; CarboEtop-3; etoposide 100 mg/m2 intravenously on days 1, 2, and 3, and carboplatin AUC 4 or 5 intravenously on day 1, every 21 days; CarboEtop-4; etoposide 120 mg/m2 intravenously on day 1 and 100-150 mg twice daily orally on days 2 and 3, and carboplatin AUC 5 intravenously on day 1, every 21 days.